Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy

Journal of Biomedical Materials Research - Part A

Volumn 101, Issue 12, 2013, Pages 3646-3660

  Mishra, Deepa ^a   Hubenak, Justin R ^a   Mathur, Anshu B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

drug delivery; nanoparticles; pharmacokinetics; targeting; therapeutic efficacy

Indexed keywords

DEGRADATION PROFILES; DRUG DELIVERY APPLICATIONS; DRUG DELIVERY SYSTEM; MATERIAL COMPOSITIONS; NANOPARTICLE SURFACE; NANOPARTICLE SYSTEMS; TARGETING; THERAPEUTIC EFFICACY;

DRUG DELIVERY; PHARMACOKINETICS;

NANOPARTICLES;

ALBUMIN; ALUMINUM OXIDE; CARBON NANOTUBE; CREMOPHOR; DENDRIMER; ELASTIN; EMODIN; GADOLINIUM; GELATIN; GOLD NANOPARTICLE; HUMAN GROWTH HORMONE; INFLUENZA VACCINE; INSULIN; IRON OXIDE; LIPOSOME; MACROGOL; NANOPARTICLE; OLIGONUCLEOTIDE; OLIGOPEPTIDE; PACLITAXEL; PLATINUM NANOPARTICLE; POLYAMIDOAMINE; POLYCAPROLACTONE; POLYETHYLENEIMINE; POLYSACCHARIDE; QUANTUM DOT; SILICON DIOXIDE; SILK FIBROIN; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE;

ANTIMICROBIAL ACTIVITY; ATOMIC FORCE MICROSCOPY; CERAMICS; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CIRCULATION TIME; CLINICAL EFFECTIVENESS; CROSS LINKING; DEGRADATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; EXCRETION; GENE TARGETING; GENE THERAPY; HUMAN; HYDROPHOBICITY; INFRARED SPECTROSCOPY; KIDNEY CLEARANCE; LENTIVIRINAE; LIPID MEMBRANE; MICELLE; NANOENCAPSULATION; PARTICLE SIZE; RETICULOENDOTHELIAL SYSTEM; RETROVIRUS; REVIEW; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SYSTEMIC CIRCULATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

DRUG DELIVERY; NANOPARTICLES; PHARMACOKINETICS; TARGETING; THERAPEUTIC EFFICACY;

ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; TREATMENT OUTCOME;

EID: 84886724604     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34642     Document Type: Review

References (117)

1. Saha RN, Vasanthakumar S, Bende G, Snehalatha M,. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol Membr Biol 2010; 27: 215-231.
2. Lim SB, Banerjee A, Onyuksel H,. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012; 163: 34-45.
3. Sanna V, Roggio AM, Siliani S, Piccinini M, Marceddu S, Mariani A, Sechi M,. Development of novel cationic chitosan- and anionic alginate-coated poly(D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int J Nanomedicine 2012; 7: 5501-5516.
4. Ibrahim BM, Park S, Han B, Yeo Y,. A strategy to deliver genes to cystic fibrosis lungs: A battle with environment. J Control Release 2011; 155: 289-295.
5. Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM,. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int J Pharm 2011; 406: 163-172.
6. Wang AZ, Langer R, Farokhzad OC,. Nanoparticle delivery of cancer drugs. Ann Rev Med 2012; 63: 185-198.
7. Farokhzad OC, Langer R,. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3: 16-20.
8. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE,. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009; 61: 428-437.
9. Hawkins MJ, Soon-Shiong P, Desai N,. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60: 876-885.
10. Torchilin V,. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63: 131-135.
11. Duceppe N, Tabrizian M,. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv 2010; 7: 1191-1207.
12. Amoozgar Z, Yeo Y,. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4: 219-233.
13. Bessa PC, Machado R, Nürnberger S, Dopler D, Banerjee A, Cunha AM, Rodríguez-Cabello JC, Redl H, van Griensven M, Reis RL, Casal M. Thermoresponsive self-assembled elastin-based nanoparticles for delivery of BMPs. J Control Release 2010; 142: 312-318.
14. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H,. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomacromolecules 2005; 26: 5898-5906.
15. Heneweer C, Gendy SEM, Penate-Medina O,. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv 2012; 3: 645-656.
16. Boddohi S, Moore N, Johnson PA, Kipper MJ,. Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan. Biomacromolecules 2009; 10: 1402-1409.
17. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z,. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008; 60: 1650-1662.
18. Zhou S, Mody D, DeRavin SS, Hauer J, Lu T, Ma Z, Hacein-Bey Abina S, Gray JT, Greene MR, Cavazzana-Calvo M, Malech HL, Sorrentino BP. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 2010; 116: 900-908.
19. Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C,. Alphavirus vectors for cancer therapy. Virus Res 2010; 153: 179-196.
20. Dani SU,. The challenge of vector development in gene therapy. Braz J Med Biol Res 1999; 32: 133-145.
21. Cai S, Zhang Q, Bagby T, Forrest ML,. Lymphatic drug delivery using engineering liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011; 63: 901-908.
22. Jesorka A, Orwar O,. Liposomes: Technologies and analytical applications. Annu Rev Anal Chem 2008; 1: 801-832.
23. Parhi R, Suresh P,. Preparation and characterization of solid lipid nanoparticles: A review. Curr Drug Discov Technol 2012; 9: 2-16.
24. Ziello JE, Huang Y, Jovin IS,. Cellular endocytosis and gene delivery. Mol Med 2010; 16: 222-229.
25. Un K, Sakai-Kato K, Oshima Y, Kawanishi T, Okuda H,. Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. Biomaterials 2012; 33: 8131-8141.
26. Venishetty VK, Samala R, Komuravelli R, Kuncha M, Sistla R, Diwan PV,. β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain. Nanomedicine 2013; 9: 388-397.
27. Meunier F, Prentice HG, Ringdãn O,. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28: 83-91.
28. Park JW,. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002; 4: 95-99.
29. Hong RL,. Liposomal anti-cancer drug researches the myth of long circulation. J Chin Oncol Soc 2004; 20: 10-21.
30. D'Acremont V, Herzog C, Genton B,. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in the elderly. J Travel Med 2006; 13: 78-83.
31. Usonis V, Bakasenas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C,. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®). Vaccine 2003; 21: 4588-4592.
32. ® V-a virosomal adjuvanted influenza vaccine. Vaccine 2009; 27: 4381-4387.
33. Gupta V, Mun GH, Choi B, Aseh A, Mildred L, Patel A, Zhang Q, Price JE, Chang D, Robb G, Mathur AB,. Repair and reconstruction of a resected tumor defect using a composite of tissue flap-nanotherapeutic-silk fibroin and chitosan scaffold. Ann Biomed Eng 2011; 39: 2374-2387.
34. Christian DA, Cai S, Bowen DM, Kim Y, Pajerowski JD, Discher DE,. Polymersome carriers: From self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm 2009; 71: 463-474.
35. Anhorn MG, Mahler H-C, Langer K,. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int J Pharm 2008; 363: 162-169.
36. Mathur AB, Gupta V,. Silk fibroin-derived nanoparticles for biomedical applications. Nanomedicine (Lond) 2010; 5: 807-820.
37. Jahanshahi M, Babaei Z,. Protein nanoparticle: A unique system as drug delivery vehicles. Afr J Biotechnol 2008; 7: 4926-4934.
38. Desai N,. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012; 14: 282-295.
39. Kim KR, Ahn KY, Park JS, Lee KE, Jeon H, Lee J,. Lyophilization and enhanced stability of fluorescent protein nanoparticles. Biochem Biophys Res Commun 2011; 408: 225-229.
40. Domingo-Espin J, Unzueta U, Saccardo P, Rodriguez-Carmona E, Corchero JL, Vazquez E, Ferrer-Miralles N,. Engineered biological entities for drug delivery and gene therapy protein nanoparticles. Prog Mol Biol Transl Sci 2011; 104: 247-298.
41. Tataru G, Popa M, Desbrieres J,. Magnetic microparticles based on natural polymers. Int J Pharm 2011; 404: 83-93.
42. Saravanakumar G, Jo DG, Park JH,. Polysaccharide-based nanoparticles: A versatile platform for drug delivery and biomedical imaging. Curr Med Chem 2012; 19: 3212-3229.
43. Dunnhaupt S, Barthelmes J, Iqbal J, Perera G, Thurner CC, Friedl H, Bernkop-Schnurch A,. In vivo evaluation of an oral drug delivery system for peptides based on S-protected thiolated chitosan. J Control Release 2012; 160: 477-485.
44. Chakravarthi SS, Robinson DH, De S,. Nanoparticles prepared using natural and synthetic polymers. In:, Thassu D, Deleers M, Pathak Y, editors. Nanoparticulate Drug Delivery Systems. New York: Taylor & Francis, LLC; 2007. p 51-60.
45. Watanabe D,. Medical application of herpes simplex virus. J Dermatol Sci 2010; 57: 75-82.
46. DiPrimio N, McPhee SW, Samulski RJ,. Adeno-associated virus for the treatment of muscle diseases: Toward clinical trials. Curr Opin Mol Ther 2010; 12: 553-560.
47. Liu RB, Rabkin SD,. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J 2005; 118: 307-312.
48. Manchester M, Singh P,. Virus-based nanoparticles (VNPs): Platform technologies for diagnostic imaging. Adv Drug Deliv Rev 2006; 58: 1505-1522.
49. Glover DJ,. Artificial viruses: Exploiting viral trafficking for therapeutics. Infect Disord Drug Targets 2012; 12: 68-80.
50. Kaiser CR, Flenniken ML, Gillitzer E, Harmsen AL, Harmsen AG, Jutila MA, Douglas T, Young MJ,. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomedicine 2007; 2: 715-733.
51. Mishra D, Kang HC, Bae YH,. Reconstitutable charged polymeric (PLGA)2-b-PEI micelles for gene therapeutics delivery. Biomaterials 2011; 32: 3845-3854.
52. Hughes GA,. Nanostructure-mediated drug delivery. Nanomedicine 2005; 1: 22-30.
53. Gajbhiye V, Palanirajan VK, Tekade RK, Jain NK,. Dendrimers as therapeutic agents: A systemic review. J Pharm Pharmacol 2009; 61: 989-1003.
54. Gao Y, Gao G, He Y, Liu T, Qi R,. Recent advances of dendrimers in delivery of genes and drugs. Mini Rev Med Chem 2008; 8: 889-900.
55. Moghimi SM, Hunter AC, Andresen TL,. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Ann Rev Pharmacol Toxicol 2012; 52: 481-503.
56. van der Pol DG, Kieler-Ferguson HM, Floyd WC, Guillaudeu SJ, Jerger K, Szoka FC, Frechet JM,. Design, synthesis and biological evaluation of a robust, biodegradable dendrimer. Bioconj Chem 2010; 21: 764-773.
57. Jain JP, Ayen WY, Kumar N,. Self assembling polymers as polymersomes for drug delivery. Curr Pharm Des 2011; 17: 65-79.
58. Tanner P, Baumann P, Enea R, Onaca O, Palivan C, Meier W,. Polymeric vesicles: From drug carriers to nanoreactors and artificial organelles. Acc Chem Res 2011; 44: 1039-1049.
59. Egli S, Nussbaumer MG, Balasubramanian V, Chami M, Bruns N, Palivan C, Meier W,. Biocompatible functionalization of polymersome surfaces: A new approach to surface immobilization and cell targeting using polymersomes. J Am Chem Soc 2011; 133: 4476-4483.
60. Hoffman AS,. The origins and evolution of controlled drug delivery systems. J Control Release 2008; 132: 153-163.
61. Kim S, Shi Y, Kim JY, Park K, Cheng J-X,. Overcoming the barriers in micellar drug delivery: Loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv 2010; 7: 49-62.
62. Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, Zhong Z,. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010; 31: 2408-2416.
63. Kakizawa Y, Kataoka K,. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 2002; 54: 203-222.
64. Hu F-Q, Zhang Y-Y, You J, Yuan H, Du Y-Z,. pH Triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy. Mol Pharm 2012; 9: 2469-2478.
65. Davis ME, Chen Z, Shin D,. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-782.
66. Sahay G, Batrakova EV, Kabanov AV,. Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. Bioconj Chem 2008; 19: 2023-2029.
67. Longmire M, Choyke PL, Kobayashi H,. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine (Lond) 2008; 3: 703-717.
68. Canal F, Sanchis J, Vincent MJ,. Polymer-drug conjugates as nano-sized medicines. Curr Opin Biotechnol 2011; 22: 894-900.
69. Etrych T, Subr V, Strohalm J, Sirova M, Rihova B, Ulbrich K,. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. J Control Release 2012; 164: 346-354.
70. Vincent MJ, Ringsdorf H, Duncan R,. Polymer therapeutics: Clinical applications and challenges for development. Adv Drug Deliv Rev 2009; 61: 1117-1120.
71. Shaffer SA, Baker-Lee C, Kennedy J, Lai MS, de Vries P, Buhler K, Singer JW,. In vitro and in vivo metabolism of paclitaxel poliglumex: Identification of metabolites and active proteases. Cancer Chemother Pharmacol 2007; 59: 537-548.
72. Manju S, Sreenivasan K,. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci 2011; 359: 318-325.
73. Goldberg M, Langer R, Jia X,. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 2007; 18: 241-268.
74. Geethalakshmi R, Sarada D,. Gold and silver nanoparticles from Trianthema decandra: Synthesis, characterization, and antimicrobial properties. Int J Nanomedicine 2012; 7: 5375-5384.
75. Ghosh P, Han G, De M, Kim CK, Rotello VM,. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008; 60: 1307-1315.
76. Yeh Y-C, Creran B, Rotello VM,. Gold nanoparticles: Preparation, properties, and applications in bionanotechnology. Nanoscale 2012; 4: 1871-1880.
77. Llevot A, Astruc D,. Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancer. Chem Soc Rev 2012; 41: 242-257.
78. Rana S, Bajaj A, Mout R, Rotello VM,. Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 2012; 64: 200-216.
79. Bisker G, Yeheskely-Hayon D, Minai L, Yelin D,. Controlled release of Rituximab from gold nanoparticles for phototherapy of malignant cells. J Control Release 2012; 162: 303-309.
80. Zhou C, Hao G, Thomas P, Liu J, Yu M, Sun S, Öz OK, Sun X, Zheng J,. Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics. Ange Chem Int Ed Engl 2012; 51: 10118-10122.
81. Kim SW, Jung JH, Lamsal K, Kim YS, Min JS, Lee YS,. Antifungal effects of silver nanoparticles (AgNPs) against various plant pathogenic fungi. Mycobiology 2012; 40: 53-58.
82. Sekhon BS, Kamboj SR,. Inorganic nanomedicine-Part 2. Nanomedicine (Lond) 2010; 6: 612-618.
83. Lem KW, Choudhury A, Lakhani AA, Kuyate P, Haw JR, Lee DS, Iqbal Z, Brumlick CJ,. Use of nanosilver in consumer products. Recent Pat Nanotechnol 2012; 6: 60-72.
84. De Jong W, Borm P,. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine 2008; 3: 133-149.
85. Glazer ES, Curley SA,. Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer 2010; 116: 3285-3293.
86. Slowing II, Vivero-Escoto JL, Wu CH, Lin VS,. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008; 60: 1278-1288.
87. Yang L, Sheldon BW, Webster TJ,. Nanophase ceramics for improved drug delivery: Current opportunities and challenges. Am Ceram Soc Bull 2010; 89: 24-31.
88. Jin Z, Hildebrandt N,. Semiconductor quantum dots for in vitro diagnostics and cellular imaging. Trends Biotechnol 2012; 30: 394-403.
89. Nathwani BB, Jaffari M, Juriani AR, Mathur AB,. Fabrication and characterization of silk fibroin-coated quantum dots. IEEE Trans Nanobiosci 2009; 8: 72-77.
90. Pericleous P, Gazouli M, Lyberopoulou A, Rizos S, Nikiteas N, Efstathopoulos EP,. Quantum dots hold promise for early cancer imaging and detection. Int J Cancer 2012; 131: 519-528.
91. Ruan G, Agrawal A, Marcus AI, Nie S,. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: New insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc 2007; 129: 14759-14766.
92. Yezhelyev MV, Al-Hajj A, Morris C, Marcus AI, Liu T, Lewis M, Cohen C, Zrazhevskiy P, Simons JW, Rogatko A, Nie S, Gao X, O'Regan RM,. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv Mater 2007; 19: 3146-3151.
93. Schroder O, Stein J,. Low dose methotrexate in inflammatory bowel disease: Current status and future directions. Am J Gastroenterol 2003; 98: 530-537.
94. Xu ZP, Zeng QH, Lu GQ, Yu AB,. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006; 61: 1027-1040.
95. Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K,. Advancement in carbon nanotubes: Basics, biomedical applications and toxicity. J Pharm Pharmacol 2010; 63: 141-163.
96. Mandani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM,. A new era of cancer treatment: Carbon nanotubes as drug delivery tools. Int J Nanomedicine 2011; 6: 2963-2979.
97. Zhang Y, Bai Y, Yan B,. Functionalized carbon nanotubes for potential medical applications. Drug Discov Today 2010; 15: 428-435.
98. Gupta V, Aseh A, Rios CN, Aggarwal BB, Mathur AB,. Fabrication and characterization of silk fibron-derived curcumin nanoparticles for cancer therapy. Int J Nanomedicine 2009; 4: 115-122.
99. Rajendran NN, Natrajan R, Siva Kumar R, Sevaraj S,. Acyclovir-loaded chitosan nanoparticles for ocular delivery. Asian J Pharm 2010; 4: 220-226.
100. Khalil NM, Nascimento TC, Casa DM, Dalmolin LF, Mattos AC, Hoss I, Romano MA, Mainardes RM,. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2012; 101C: 353-360.
101. Porter RS,. The Merck Manual for Healthcare Professionals, 19 ed (Vol. 2012). New Jersey: Merck; 2011.
102. Gao C, Liu M, Chen J, Chen C,. pH- and temperature-responsive P(DMAEMA-GMA)-alginate semi-IPN hydrogels formed by radical and ring-opening polymerization for aminophylline release. J Biomater Sci Polym Ed 2011 [Epub ahead of Print].
103. Pierre MB, Dos Santos Miranda Costa I,. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res 2011; 303: 607-621.
104. Müller RH, Gohla S, Keck CM,. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011; 78: 1-9.
105. Du J, Jin J, Yan M, Lu Y,. Synthetic nanocarriers for intracellular protein delivery. Curr Drug Metab 2012; 13: 82-92.
106. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C,. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study. Lancet Oncol 2012; S1470-S2045: 70476-X.
107. Ling SS, Magosso E, Khan NA, Yuen KH, Barker SA,. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 2006; 32: 335-345.
108. Sun M, Hoffman D, Sundaresan G, Yang L, Lamichhane N, Zweit J,. Synthesis and characterization of intrinsically radiolabeled quantum dots for biomodal detection. Am J Nucl Med Imaging 2012; 2: 122-135.
109. Jensen BC, McLeod HL,. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 2013; 14: 205-213.
110. Golla K, Cherukuvada B, Ahmed F, Kondapi AK,. Efficacy, safety, and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS ONE 2012; 7: e51960.
111. 4 nanoparticles following intravenous injection using scanning SQUID biosusceptometry. PLoS ONE 2012; 7: e48510.
112. Li S-D, Huang L,. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5: 496-504.
113. Borak B, Biernat P, Prescha A, Baszczuk A, Pluta J,. In vivo study on the biodistribution of silica particles in the bodies of rats. Adv Clin Exp Med 2012; 21: 13-18.
114. Cho M, Cho WS, Choi M, Kim SJ, Han BS, Kim SH, Kim HO, Sheen YY, Jeong J,. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett 2009; 189: 177-183.
115. Kim D, Lee ES, Oh KT, Gao ZG, Bae YH,. Doxorubicin-loaded polymeric micelles overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008; 4: 2043-2050.
116. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K,. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004; 12: 461-471.
117. Calorini L, Peppicelli S, Bianchini F,. Extracellular acidity as favouring factor of tumor progression and metastatic dissemination. Exp Oncol 2012; 34: 79-84.